コンテンツへスキップ
Merck

I1762

Supelco

Isoxicam

analytical standard

別名:

4-Hydroxy-2-methyl-N-5-methyl-3-isoxolyl-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide

ログイン組織・契約価格を表示する


About This Item

実験式(ヒル表記法):
C14H13N3O5S
CAS番号:
分子量:
335.34
EC Number:
MDL番号:
UNSPSCコード:
41116107
PubChem Substance ID:
NACRES:
NA.24

グレード

analytical standard

品質水準

テクニック

HPLC: suitable
gas chromatography (GC): suitable

アプリケーション

forensics and toxicology
pharmaceutical (small molecule)
veterinary

フォーマット

neat

SMILES記法

CN1C(C(=O)Nc2cc(C)on2)=C(O)c3ccccc3S1(=O)=O

InChI

1S/C14H13N3O5S/c1-8-7-11(16-22-8)15-14(19)12-13(18)9-5-3-4-6-10(9)23(20,21)17(12)2/h3-7,18H,1-2H3,(H,15,16,19)

InChI Key

YYUAYBYLJSNDCX-UHFFFAOYSA-N

遺伝子情報

詳細

Isoxicam is a long acting anti-inflammatory agent belonging to the oxicam group, and helps in relieving the symptoms of degenerative joint disease and rheumatoid arthritis. Its mode of action involves the ability to inhibit prostaglandin synthesis by suppressing the formation of cyclooxygenase and subsequent prostaglandin.

アプリケーション

Isoxicam may be used as an internal standard for the quantification of meloxicam in pharmaceutical preparations and as an analytical reference standard for the quantification of the analyte in biological samples using different analytical techniques.
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

保管分類コード

11 - Combustible Solids

WGK

WGK 2

引火点(°F)

Not applicable

引火点(℃)

Not applicable

個人用保護具 (PPE)

Eyeshields, Gloves, type N95 (US)


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Jan Code

I1762-BULK:
I1762-5G:
I1762-1G:
I1762-VAR:
I1762-10G:


最新バージョンのいずれかを選択してください:

試験成績書(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 資料 section.

サポートが必要な場合は、お問い合わせください カスタマーサポート

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

N Bellamy et al.
The Journal of rheumatology, 15(12), 1833-1840 (1988-12-01)
Within the context of a double blind randomized controlled parallel trial of 2 nonsteroidal antiinflammatory drugs, we validated WOMAC, a new multidimensional, self-administered health status instrument for patients with osteoarthritis of the hip or knee. The pain, stiffness and physical
T F Woolf et al.
Drug metabolism and disposition: the biological fate of chemicals, 17(6), 662-668 (1989-11-01)
Isoxicam is a long half-life nonsteroidal anti-inflammatory agent which undergoes extensive metabolism prior to elimination in animals and man. The major route of isoxicam transformation is hydroxylation of the methylisoxazole functionality to form hydroxymethylisoxicam, and cleavage of its benzothiazine moiety
G Caillé et al.
Biopharmaceutics & drug disposition, 8(1), 57-61 (1987-01-01)
This study was designed to determine whether the disposition of isoxicam is influenced by the coadministration of another acidic drug, highly bound to plasma proteins and extensively metabolized, i.e., phenytoin. Ten healthy volunteers received an oral dose of 200 mg
W Frankhof
Current medical research and opinion, 11(1), 28-33 (1988-01-01)
The therapeutic efficacy and tolerability of a new controlled-release 1000 mg tablet of naproxen (naproxen CR) were compared with 200 mg isoxicam in 100 out-patients with osteoarthritis. Medications were administered once daily for 4 weeks in a controlled, randomized, double-blind
A review of HPLC methods used for determining the presence of meloxicam
Brezovska M, et al.
Current Pharmaceutical Analysis, 9(1), 69-76 (2013)

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)